Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
Tumor immunotherapy is currently a hot research topic in the field of oncology, and is an efficacious mode of tumor treatment. Programmed cell death receptor PD-1 (PD-1) is an important immunosuppressive molecule, which is mainly expressed in activated T and B cells. PD-1/PD-L1 inhibitors can block...
Saved in:
Published in | BIO web of conferences Vol. 55; p. 1007 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
EDP Sciences
01.01.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Tumor immunotherapy is currently a hot research topic in the field of oncology, and is an efficacious mode of tumor treatment. Programmed cell death receptor PD-1 (PD-1) is an important immunosuppressive molecule, which is mainly expressed in activated T and B cells. PD-1/PD-L1 inhibitors can block the binding of PD-1 to PD-L1, block the negative regulatory signals, and restore the activity of T cells, thus enhancing the immune response. |
---|---|
ISSN: | 2117-4458 2117-4458 |
DOI: | 10.1051/bioconf/20225501007 |